Liraglutide vs GHK-Cu
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
LiraglutideSkin & CosmeticRecovery & RepairAnti-Aging & Longevity
GHK-Cu- Summary
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- GHK-Cu is a naturally occurring copper complex that declines with age. It is one of the most studied anti-aging peptides, known for powerful skin rejuvenation, wound healing, and tissue remodeling effects.
- Half-Life
- ~13 hours (once-daily dosing)
- 2–4 hours
- Admin Route
- SubQ
- SubQ, Topical
- Research
- —
- —
- Typical Dose
- Start 0.6 mg, titrate to 3 mg
- 1–3 mg
- Frequency
- Once daily
- 3–5 times per week
- Key Benefits
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Reduces wrinkles and fine lines
- Improves skin firmness and elasticity
- Accelerates wound healing
- Reduces inflammation and oxidative damage
- Promotes hair growth and thickness
- Supports collagen and elastin production
- May improve overall skin health and appearance
- Resets aged fibroblast behavior
- Anti-fibrotic — reduces scar tissue formation
- Side Effects
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Temporary blue-green discoloration at injection site (from copper — harmless)
- Post-injection sting (brief)
- Skin irritation with topical use (rare)
- Stacks With
- —
- —